Shop
Olaparib (brand name: Lynparza, Lipuzhuo; Beacon).
Price range: £468.00 through £591.00Olaparib produced by Beacon (generic name: Olaparib; brand names: Lynparza, Lipuzhuo) is a PARP inhibitor originally developed by AstraZeneca. It has been approved by the FDA for the treatment of various cancers, including ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer.
It works by inhibiting DNA repair enzymes, preventing cancer cells from repairing their DNA, which leads to cell death and helps delay or stop tumor progression.
Beacon Pharmaceuticals was founded in 2001 and is one of the largest and most technologically advanced manufacturers of oncology and antiviral drugs in Bangladesh. Its products comply with international GMP certifications, including those from the US FDA, UK MHRA, and Australia’s TGA.
Crizotinib (brand name: Xalkori, Sekuri; Incepta).
Original price was: £379.00.£249.00Current price is: £249.00.Crizotinib is a multi-target protein kinase inhibitor developed by Pfizer in the United States. It has demonstrated significant clinical efficacy in patients with tumors characterized by abnormal ALK, ROS1, and MET kinase activity.
MedFind provides access to Crizotinib through verified overseas procurement channels, with guaranteed authenticity, in-stock availability, rapid shipping, full logistics tracking, and privacy-protected handling. Professional guidance is available upon inquiry, including information on indications, clinical efficacy, adverse effects, and medication usage instructions.
Osimertinib (brand name: Tagrisso, Terisha; Incepta).
Original price was: £288.00.£97.00Current price is: £97.00.由 Incepta 公司生产的奥希替尼是一种第三代口服不可逆 EGFR 靶向酪氨酸激酶抑制剂 (EGFR-TKI)，由英国阿斯利康公司开发。其原商品名为泰瑞沙 (Tagrisso)，研发代号为 AZD9291。
它用于治疗晚期非小细胞肺癌（NSCLC），并选择性地抑制 EGFR 敏感突变和 EGFR T790M 耐药突变。
Ibrutinib (also translated as Yilutini; brand name: Yike; Incepta).
Original price was: £399.00.£238.00Current price is: £238.00.Ibrutinib produced by Incepta (generic name: Ibrutinib, also translated as Yilutini; brand names: Imbruvica, Yike) is an oral Bruton’s tyrosine kinase (BTK) inhibitor. It exerts its antitumor effect by inhibiting BTK, which is required for tumor cell proliferation and metastasis.
It is used for the treatment of relapsed mantle cell lymphoma, relapsed chronic lymphocytic leukemia (CLL), CLL with 17p deletion, and Waldenström’s macroglobulinemia.
Tucatinib (also translated as Tukatinib; brand name: Tukysa, Everest)
Original price was: £790.00.£570.00Current price is: £570.00.Tucatinib (also translated as Tukatinib; brand name: Tukysa) is able to inhibit the growth of tumor cells that overexpress HER2.
In 2020, the U.S. FDA approved tucatinib in combination with trastuzumab and capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have previously received one or more anti-HER2-based treatment regimens.
Alectinib (Anshengsha, Everest)
Original price was: £370.00.£194.00Current price is: £194.00.Alectinib produced by Everest (also translated as Ailetinib or Alectinib; brand name: Alecensa/Anshengsha) is a second-generation ALK inhibitor developed by the U.S. pharmaceutical company Roche.
Alectinib was first approved by the U.S. FDA in December 2015 for the treatment of non-small cell lung cancer (NSCLC) patients who had developed resistance to crizotinib. In November 2017, it was further approved for first-line treatment of advanced ALK-positive NSCLC.
Sotorasib / Lumakras (Everest)
Original price was: £450.00.£391.00Current price is: £391.00.Sotorasib, also known as Sotororese (generic name: Sotorasib, brand name: Lumakras, code name: AMG510), is a covalent inhibitor of the KRAS G12C mutant. It binds to the KRAS G12C mutant protein, locking KRAS in its inactive state and thereby irreversibly inhibiting its activity.
Clinical trial results showed that patients treated with Sotorasib achieved an overall response rate (ORR) of 36% (95% CI: 28–45), a disease control rate (DCR) of 81% (95% CI: 73–87), and a median duration of response of 10 months. After more than 40 years of research on KRAS-mutant oncogenic proteins, Sotorasib became the world’s first approved KRAS G12C inhibitor.
Larotrectinib / Vitrakvi (Everest)
Price range: £269.00 through £554.00Larotrectinib (Brand name: Vitrakvi) manufactured by Everest Pharma is a targeted therapy used for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring NTRK gene fusions, regardless of where the cancer originated in the body.
Larotrectinib became the first FDA-approved tumor-agnostic targeted therapy based solely on the presence of a specific genetic mutation rather than cancer type or tumor location.
Clinical studies demonstrated efficacy across 17 different adult and pediatric tumor types, highlighting its broad-spectrum anticancer activity in patients with NTRK fusion-positive cancers.
Cabozantinib (Everest)
Original price was: £299.00.£245.00Current price is: £245.00.Cabozantinib manufactured by Everest Pharma is a multi-target broad-spectrum anticancer therapy that has demonstrated promising clinical efficacy across a wide range of solid tumors.
Cabozantinib has shown beneficial treatment effects in:
- Renal cell carcinoma (kidney cancer)
- Thyroid cancer
- Liver cancer
- Soft tissue sarcoma
- Non-small cell lung cancer (NSCLC)
- Prostate cancer
- Breast cancer
- Ovarian cancer
- Colorectal cancer
and several other advanced malignancies.
Cabozantinib is particularly recognized for its strong effectiveness in controlling bone metastases, helping reduce tumor progression and complications associated with metastatic bone disease.
Due to its broad antitumor activity across multiple cancer types, Cabozantinib is often referred to as a “multi-purpose” or “broad-spectrum” targeted therapy among tyrosine kinase inhibitors (TKIs).
Niraparib / Zejula (Everest)
Original price was: £344.00.£244.00Current price is: £244.00.Niraparib (also known as Niraparib; Brand name: Zejula) is a PARP inhibitor used for maintenance treatment of advanced recurrent ovarian cancer.
Niraparib has been shown to significantly prolong progression-free survival and help reduce the risk of ovarian cancer recurrence in patients with advanced disease.
MedFind provides overseas sourcing services for Niraparib through regulated international channels, with authenticity assurance, fast shipment availability, full logistics tracking, and encrypted privacy protection throughout the process.
Learn more about indications, side effects, and medication guidance.
Olaparib / Lynparza (Everest)
Price range: £163.00 through £325.00Olaparib (also known as Olaparib; Brand name: Lynparza) is a PARP inhibitor used for the treatment of ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer.
In addition to its approved indications, Olaparib has shown promising efficacy across multiple tumor types and is increasingly recognized for its potential as a broad-spectrum targeted anticancer therapy.
MedFind provides overseas sourcing services for Olaparib through regulated international channels, with authenticity assurance, fast shipment availability, full logistics tracking, and encrypted privacy protection throughout the process.